The civic record
Read. Follow. Verify.Idaho Requires Explicit Product Labeling for Items Involving Human Fetal Tissue and Establishes Civil Penalties
Last action · February 17, 2026: Reported Printed; referred to Commerce & Human Resources
Track this bill to get notified when it advances a stage. One tap to stop, anytime.
What This Bill Proposed
HUMAN FETAL TISSUE – Adds to existing law to establish provisions regarding the use of human fetal tissue in products.
Manufacturers and retailers selling goods in Idaho must implement new tracking and labeling systems to disclose the use of fetal tissue or face financial penalties up to 5% of state sales, while consumers receive mandatory point-of-purchase disclosures starting July 1, 2026.
Who It Would Have Affected
Groups the bill's text would have affected, as described in the record. Being affected is not a position for or against it.
Manufacturers of medical products and vaccinations
Manufacturers are subject to strict liability for labeling violations and must update packaging and supply chain verification policies.
Retailers selling goods in Idaho
Retailers face liability if they sell unlabeled products with actual knowledge that labeling was required.
Office of the Attorney General
The attorney general is empowered to investigate violations, seek injunctions, and collect civil penalties.
Key Facts
- Mandates explicit labeling on all products, vaccinations, or medical items using ingredients or additives subjected to human fetal tissue in testing, production, or development.
- Applies labeling requirements to final product testing, components, materials, and specific production lots or batches.
- Imposes strict liability on manufacturers for labeling violations, while retailers are liable only if they had actual knowledge of the violation and failed to label.
- Authorizes the attorney general to bring actions for injunctive relief and civil penalties up to $5,000 per violation or 5% of the gross revenue derived from the violating product's state sales.
Show all 8 facts
- Provides affirmative defenses including conspicuous consumer notification online or vocally in-person, established manufacturer compliance policies, and retailer reliance on manufacturer labeling.
- Clarifies that out-of-state status is not an affirmative defense for manufacturers or retailers.
- Defines 'human fetal tissue' to include tissue or cells from a dead human embryo or fetus, embryonic cell lines, and derivative biological matter like DNA or proteins.
- Declares an emergency and sets the effective date as July 1, 2026.
Frequently Asked Questions
Which products are subject to the new labeling requirement?
What penalties can businesses face for non-compliance?
What else do you want to know?
News Coverage
Follow the record
Votes, people, money & the original sourceWhere This Stands
This bill did not become law - Died at adjournment · in Senate committee.
Procedural history
2 actions- Feb 17, 2026CommitteeReported Printed; referred to Commerce & Human Resources
- Feb 16, 2026IntroducedIntroduced; read first time; referred to JR for Printing
Version history
Only one version on file - nothing to compare yet. As later stages (committee substitute, engrossed, enrolled) are captured, the redline appears here.
View official text →Lobbying Activity
No state lobbying filings in our records match this bill. Federal lobbying reports (LDA) cover Congress, so they are not listed on state bills.
Full breakdown
Who this bill affects and the strongest case for and against it, written only from the bill’s own text.
Connected Entities
Sources
legislature.idaho.gov
Analysis Score
0–100- Significance20Lowered because this bill did not pass (its text scored 75)
- Controversy85Intensity of disagreement among stakeholders
- Entertainment10Compellingness for a non-policy-wonk reader
- Buzz50Current news / social attention level
Publisher tools